Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Bruce J. Roth, Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Marcia S. Brose(Sidney Kimmel Cancer Center), Eric Larsen(University of Massachusetts Chan Medical School), David I. Quinn(USC Norris Comprehensive Cancer Center), Wolfram E. Samlowski(University of Utah), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Sylvia Adams(NYU Langone Health), Joseph O. Jacobson(Dana-Farber Cancer Institute), Ann H. Partridge(Dana-Farber Cancer Institute), Lee M. Ellis(The University of Texas MD Anderson Cancer Center), Daniel J. George(Duke University), Harry P. Erba(Michigan Center for Translational Pathology), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Leslie L. Robison(St. Jude Children's Research Hospital), Lada Krilov(American Society of Clinical Oncology), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Stuart M. Lichtman(Memorial Sloan Kettering Cancer Center), Jamie H. Von Roenn(American Society of Clinical Oncology), Peter B. Bach(CCC Diagnostics (United States)), Fadi Braiteh(Opexa Therapeutics (United States)), Gary K. Schwartz(Baylor University Medical Center)
Cited by 63
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k